Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD

Inclusion Criteria

• •For patients and healthy volunteers:
• •* Age between 18 and 80 years.
• •* Non-diabetic participant (fasting blood glucose \< 1.26 g/L, or absence of insulin therapy or oral antidiabetic medication).
• •* Body mass index (BMI) between 18 and 30 kg/m².
• •* For women of childbearing potential, use of at least one recognized effective contraceptive method.
• •* Very regular bowel movements every 24 to 48 hours.
• •* Participant living within 100 km of the Lyon Sud Hospital Center (CHLS).
• •* Participant willing to participate in the study and providing written informed consent.
• •* Participant affiliated with the general French Social Security system or an equivalent scheme.
• •For patients:
• •* Presence of MASLD according to the definition of the European Association for the Study of the Liver (EASL), defined by hepatic steatosis on imaging performed within the previous year (abdominal ultrasound, abdominal CT scan, magnetic resonance imaging, or controlled attenuation parameter (CAP) measured by FibroScan) and at least one cardiometabolic criterion among: dyslipidemia, arterial hypertension, overweight (BMI ≥ 25 kg/m²), impaired glucose tolerance, or type 2 diabetes.
• •* No history of liver transplantation.
• •* No excessive alcohol consumption (less than 20 g/day for women and less than 30 g/day for men).
• •* Patient followed in the Endocrinology, Diabetes and Nutrition Department at Lyon Sud Hospital.